Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer.

ABSTRACT:

Importance

Proton pump inhibitors (PPIs) are commonly used drugs to relieve gastrointestinal tract symptoms, but their acid-inhibitory action negatively affects the bioavailability and clinical outcomes of orally administered concomitant drugs.

Objective

To identify the clinical outcomes of patients with advanced breast cancer who concomitantly use PPIs and palbociclib.

Design, setting, and participants

This retrospective cohort study used nationwide claims data between November 1, 2016, and July 31, 2021, in South Korea. Patients with breast cancer receiving palbociclib between November 1, 2017, and July 31, 2020, were identified. Patients whose prescriptions for palbociclib and PPI overlapped by at least 33% were classified into a concomitant PPI group. Patients who

SUBMITTER: Lee JE 

PROVIDER: S-EPMC10362477 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature